Literature DB >> 7989758

Individual effects of the DR11-variable beta-chain residues 67, 71, and 86 upon DR(alpha,beta 1*1101)-restricted, peptide-specific T cell proliferation.

J S McKinney1, X T Fu, C Swearingen, E Klohe, R W Karr.   

Abstract

The four members of the HLA-DR11 family of class II molecules vary only by three or fewer amino acids via dimorphisms among DR beta-chain residues 67, 71, and 86. However, they differ markedly in their abilities to induce proliferation of DR(alpha,beta 1*1101)-restricted, peptide-specific T cell clones. To dissect which DR11-variable residues, individually and in combination, mediate these functional differences, we used as APC transfectants expressing DR molecules with one of all possible permutations of DR11-variable sequences, including the four DR11 family members, and four additional DR11 variant mutants. The abilities of the wild-type or mutant molecules to present two distinct influenza peptide Ags, HA307-19 and HA128-45, to T cells was assessed in in vitro T cell proliferation assays. Of the naturally dimorphic DR11 positions, residue beta 71 variation significantly influenced the ability of DR11 molecules to present both peptides to DR(alpha,beta 1*1101)-restricted T cells. Residue beta 86 variation had relatively less influence than reported in several other DR and peptide systems. Residue beta 67 variation usually appeared irrelevant to T cell proliferation, but in two mutants led to unexpected T cell proliferation independent of nominal peptide Ag. Peptide binding, assessed by flow cytometry, was not found to be altered by any mutations that disrupted DR(alpha,beta 1*1101)-like presentation. These data indicate that residue beta 71 exerts a central role in influencing the functional differences among DR11 molecules, whereas the widely studied dimorphism of residue beta 86 is not as generally influential in DR11 as in other alleles.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7989758

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  3 in total

1.  An immunodominant SSX-2-derived epitope recognized by CD4+ T cells in association with HLA-DR.

Authors:  Maha Ayyoub; Charles S Hesdorffer; Monica Montes; Andrea Merlo; Daniel Speiser; Donata Rimoldi; Jean-Charles Cerottini; Gerd Ritter; Matthew Scanlan; Lloyd J Old; Danila Valmori
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

2.  Peptide HER2(776-788) represents a naturally processed broad MHC class II-restricted T cell epitope.

Authors:  R Sotiriadou; S A Perez; A D Gritzapis; P A Sotiropoulou; H Echner; S Heinzel; A Mamalaki; G Pawelec; W Voelter; C N Baxevanis; M Papamichail
Journal:  Br J Cancer       Date:  2001-11-16       Impact factor: 7.640

3.  Shared peptide binding of HLA Class I and II alleles associate with cutaneous nevirapine hypersensitivity and identify novel risk alleles.

Authors:  Rebecca Pavlos; Elizabeth J McKinnon; David A Ostrov; Bjoern Peters; Soren Buus; David Koelle; Abha Chopra; Ryan Schutte; Craig Rive; Alec Redwood; Susana Restrepo; Austin Bracey; Thomas Kaever; Paisley Myers; Ellen Speers; Stacy A Malaker; Jeffrey Shabanowitz; Yuan Jing; Silvana Gaudieri; Donald F Hunt; Mary Carrington; David W Haas; Simon Mallal; Elizabeth J Phillips
Journal:  Sci Rep       Date:  2017-08-17       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.